TLSA tizianalifesciences.com: Market Value to Book Value Ratio
The valuation foundation of Tiziana Life Sciences (TLSA) is based on patents in the field of nasal antibody administration to combat neuroimmune pathology, which is confirmed by the share price retrospective at the level of -39.65. The business relies on the creation of monoclonal drugs with minimal costs during mass production. The operating model utilizes GMP contractors for batch synthesis, ensuring strict adherence to production schedules and the absence of disruptions.
Tiziana Life Sciences Ltd. (TLSA) - metric breakdowns and financial figures
- share price and expert price forecast:
- company stock capitalization data:
- book capitalization data:
- debt obligations and liquidity statistics:
Debt to Equity Tiziana Life Sciences|TLSA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Tiziana Life Sciences PLC|TLSA - Company Total Debt|Debts to Book Capitalization Tiziana Life Sciences PLC|TLSA - Company Long-Term Debts|Company Current Liabilities Tiziana Life Sciences|Quick Ratio tizianalifesciences.com
- earnings and valuation multiples indicators:
Basic company analysis:Tiziana Life Sciences - TLSA
Holding patents for a unique antibody delivery system, Tiziana Life Sciences (TLSA) claims pricing power, which is reflected in the market value premium over net assets. This indicator measures the gap between the exchange valuation and the book value of capital; therefore, the current market-to-book value ratio demonstrates market expectations regarding the future capitalization of the company's intellectual property.
Competitor analysis
ARGX: Market Capitalization to Book Value Ratio|biontech.de (BNTX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio abivax.com|ADMA Biologics Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio PTGX|IMVT (Immunovant Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|Market Capitalization to Book Value Ratio grifols.com GRFS|ADPT - Market Value to Book Value Ratio|Market Value to Book Value CLDX (Celldex Therapeutics Inc)|Aurinia Pharma (AUPH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio BioCryst Corp|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com|Market Cap to Net Assets Ratio PHVS (Pharvaris)|ABCL (AbCellera Biologics) - Market Value to Book Value|Market Capitalization to Book Value Ratio TRML (Tourmaline Corp)|Market Capitalization to Book Value Precigen Corp (PGEN)|PHAR - Market Value to Book Value Ratio|nektar.com (NKTR) - Market Cap to Net Assets Ratio|Upstream Bio (UPB) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|Market Cap to Net Assets Ratio IMNM|Market Capitalization to Book Value Ratio Gossamer Bio Corp.|Market Value to Book Value Ratio KalVista Pharmaceuticals (KALV)|septerna.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio PVLA (Pieris Pharmaceuticals, Inc.)|Savara Inc (SVRA) - Market-to-Book Ratio|RIGL: Market Cap to Net Assets Ratio|AnaptysBio Inc. - Market Cap to Book Value Multiple|ATXS: Market Capitalization to Book Value Ratio|ENGN - Market Capitalization to Book Value|Market Cap to Net Assets Ratio RAPT|Aerovate - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio ACRS|Market Capitalization to Book Value Kyverna Therapeutics, Inc|Market Capitalization to Book Value Ratio CABA (Cabaletta Bio, Inc.)|Market Capitalization to Book Value Ratio ventyxbio.com VTYX|THTX - Market Value to Book Value Ratio|AVTX (Avalo Therapeutics, Inc.) - Capitalization to Book Value Ratio|ELDN: Market Capitalization to Book Value Ratio|Agenus, Inc (AGEN) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio CLYM|ZURA: Market Value to Book Value|Market Value to Book Value Ratio aTyr Pharma (ATYR)|Market Value to Book Value Ratio ADAG (adagene.com)|Market Capitalization to Book Value Ratio IMA (Ikena Oncology)|Market Capitalization to Book Value Shattuck Labs Inc (STTK)|Equillium Bio - Market Capitalization to Book Value Ratio|Market Capitalization to Net Assets CNTB|IMUX: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Atara Bio (ATRA)|Market Cap to Net Assets Ratio IFRX|XFOR: Market Value to Book Value|Market Value to Book Value Ratio Adicet Bio (ACET)|Market Capitalization to Book Value celularity.com|Market Capitalization to Book Value Ratio INMB (INmune Bio)|BRNS - Market Cap to Net Assets Ratio|Kezar Life Sciences, Inc - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value SAB Biotherapeutics Inc SABS|AKTX: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Enlivex Therapeutics Ltd. (ENLV)|Market Value to Book Value Ratio Q32 Bio Inc|Capitalization to Book Value Ratio GOVX (GeoVax Labs)|Market Capitalization to Book Value Ratio EDSA|Market Cap to Net Assets Ratio iBio Corporation IBIO|Market Capitalization to Book Value Ratio CARM (Carisma Therapeutics Inc.)|xtlbio.com (XTLB) - Market-to-Book Ratio|BOLT - Market Value to Book Value Ratio|Market Capitalization to Book Value HCW Biologics Inc. HCWB|APVO (aptevotherapeutics.com) - Market Cap to Net Assets Ratio|AIM: Market Cap to Book Value Multiple|Market Value to Book Value Ratio Aditxt Inc.|Market Value to Book Value Ratio GRI|Market Value to Book Value Ratio XORTX Therapeutics (XRTX)|Market Capitalization to Book Value Vyome Holdings Inc.|Market Capitalization to Book Value Ratio REVB (Revelation Bio)|Market Capitalization to Book Value Ratio Indaptus Corp INDP|SCNI - Market Value to Book Value Ratio|Market Capitalization to Net Assets CALI|AFMD: Market Capitalization to Book Value Ratio|Allakos - Market Value to Book Value|HOOK (HOOKIPA Pharma, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio IGM Bio|Market Value to Book Value Ratio iTeos Therapeutics (ITOS)|OCEA (oceanbiomedical.com) - Market Value to Book Value|Market Value to Book Value Ratio TC BioPharm TCBP|THRD - Market Cap to Net Assets Ratio